A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma

201911 citationsJournal Articlegold Open Access

Authors

Brian A. Van Tine · Washington University in St. Louis

Mark Agulnik · Northwestern University

Richard D. Olson · Gem Pharmaceuticals (United States)

Gerald M. Walsh · Gem Pharmaceuticals (United States)

Arthur Klausner · Gem Pharmaceuticals (United States)

Nicole E. Frank · Idaho State University

Todd T. Talley

Abstract

These results suggest future studies are warranted to further evaluate the clinical efficacy of GPX-150 in STS, perhaps at doses higher than 265 mg/m<sup>2</sup> .

Topics & Keywords

Chemotherapy-induced cardiotoxicity and mitigation Chemotherapy-related skin toxicity Cancer Treatment and Pharmacology

Publication Details

Published in: Cancer Medicine

Volume 8, Issue 6, pp. 2994-3003

DOI: 10.1002/cam4.2136

Field-Weighted Citation Impact: 0.97

Command Palette

A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma

Authors

Abstract

Topics & Keywords

Publication Details